Literature DB >> 1280221

Functional characterization of a novel anti-B7 monoclonal antibody.

M de Boer1, P Parren, J Dove, F Ossendorp, G van der Horst, J Reeder.   

Abstract

For optimal activation of T cells, binding of their T cell receptor to antigenic peptides in the context of major histocompatibility complex molecules on antigen-presenting cells (APC) is not sufficient. Accessory signals, provided by accessory cells, are needed to induce proliferation and clonal expansion of normal T cells. It has been shown previously that the B7 molecule, present on the cell surface of activated APC, can provide the second signal by binding to the CD28 molecule on T cells. Here we describe a novel anti-B7 (mAb), B7-24. This mAb binds to a functionally important epitope of the B7 molecule. Fab fragments of B7-24 can almost completely block anti-CD3-induced, B7-dependent T cell proliferation when tested in a model system where purified T cells are co-cultured with 3T6 cells expressing the human Fc gamma RII and human B7, in the presence of anti-CD3 mAb. In contrast, mAb B7-24 is not able to inhibit T cell proliferation in primary mixed lymphocyte reactions where purified T cells are co-cultured with Epstein-Barr virus-transformed B cells. These findings suggest that other cell surface molecules allow for maximal proliferation of T cells in mixed lymphocyte reactions, even when the interaction between B7 and CD28 is blocked by B7-24.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280221     DOI: 10.1002/eji.1830221207

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

2.  Alloantigen-specific T-cell anergy induced by human keratinocytes is abrogated upon loss of cell-cell contact.

Authors:  H G Otten; B Bor; C Ververs; L F Verdonck; M De Boer; G C De Gast
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production.

Authors:  E Pinelli; V P Rutten; M Bruysters; P F Moore; E J Ruitenberg
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Effects of anti-IL-4 receptor monoclonal antibody on in vitro T cell cytokine levels: IL-4 production by T cells from non-atopic donors.

Authors:  D M Bullens; A Kasran; X Peng; K Lorré; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

5.  Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta.

Authors:  M Kruger; S Van Gool; X H Peng; L Coorevits; M Casteels-Van Daele; J L Ceuppens
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

6.  Functional analysis of synovial fluid and peripheral blood T cells from patients with rheumatoid arthritis.

Authors:  M van den Broek; L Boeije; T Swaak; R Smeenk; L Aarden
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

7.  Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.

Authors:  F A Vyth-Dreese; H Boot; T A Dellemijn; D M Majoor; L C Oomen; J D Laman; M Van Meurs; R A De Weger; D De Jong
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

8.  Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.

Authors:  I A Haagen; W B de Lau; B J Bast; A J Geerars; M R Clark; B C de Gast
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

9.  The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction.

Authors:  S W Van Gool; M de Boer; J L Ceuppens
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

10.  B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

Authors:  W C Vooijs; H G Otten; M van Vliet; A J van Dijk; R A de Weger; M de Boer; H Bohlen; A Bolognesi; L Polito; G C de Gast
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.